Journal
KIDNEY CANCER
Volume 3, Issue 3, Pages 151-161Publisher
IOS PRESS
DOI: 10.3233/KCA-190058
Keywords
Papillary renal carcinoma; kidney cancer; renal cell cancer; molecularly targeted therapies; immune-checkpoint inhibitor; non-clear cell renal cell carcinoma; MET
Categories
Funding
- Winship Cancer Institute of Emory University
- NIH/NCI [P30CA138292]
Ask authors/readers for more resources
Papillary renal cell carcinoma (PRCC) is a subtype of renal cell carcinoma (RCC) accounting for approximately 15-20% of cases and further divided into Type 1 and Type 2. Type 1 PRCC tends to have more alterations in the MET tyrosine kinase receptor than Type 2 PRCC. Treatment for RCC patients is based on studies with minimal participation from patients with PRCC; consequently, conventional therapies tend to be less effective for RCC patients with a subtype other than ccRCC (non-ccRCC). Since MET is a known alteration in PRCC, it is potential target for directed therapy. There have been many attempts to develop MET inhibitors for use in solid tumors including PRCC. The following review will discuss the current research regarding MET-targeted therapy, MET inhibitors in clinical trials, and future directions for MET inhibitors in PRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available